IMM-6101

N/A

Report date: 2022/01/19 17:59:42

Base Information

Drug NameIMM-6101

Drug Alias NameIMM-6101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitors

TargetsCluster of differentiation 47

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A